7 minute read
Oct. 24, 2023

RPT193: A Small Molecule Competing With Biologics in Immunology


oral selective CCR4 antagonist Ph. II for atopic dermatitis and T2-high asthma from optimization of FLX475 First Disclosures, ACS Fall 2023 RAPT Therapeutics, So. San Francisco, CA

Drug Hunter Team

RPT193, an oral, second-generation CCR4 inhibitor from RAPT Therapeutics, is in Ph. II clinical trials (400 mg QD) to treat atopic dermatitis (AD) and asthma. CCR4 has been a long outstanding therapeutic target for treating inflammatory diseases, but despite many efforts, no molecule inhibiting this receptor has progressed beyond Ph. I for these indications.

RPT193’s story is interesting as it’s an example of a zwitterionic drug that is orally available, and is a great example of a small molecule that could compete in immunology with biologics including but not limited to dupilumab, mepolizumab, and tezepelumab.



Other molecules you may be interested in